Peginterferon and ribavirin for chronic hepatitis C.

A 44-year-old woman with chronic hepatitis C has intermittent fatigue and persistent elevations in serum alanine aminotransferase levels. Treatment with peginterferon and ribavirin is recommended. Combination therapy with these two agents can lead to sustained viral control and improvement in histologic features of the liver. Side effects of therapy and treatment failures are common.

[1]  H. Conjeevaram,et al.  Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. , 2006, Gastroenterology.

[2]  M. Alter,et al.  The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002 , 2006, Annals of Internal Medicine.

[3]  L. Gluud,et al.  Ribavirin Monotherapy for Chronic Hepatitis C Infection: A Cochrane Hepato-Biliary Group Systematic Review and Meta-Analysis of Randomized Trials , 2006, The American Journal of Gastroenterology.

[4]  R. Bartenschlager,et al.  The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. , 2006, Journal of hepatology.

[5]  A. el-Zayadi,et al.  Response of Hepatitis C Genotype-4 Naïve Patients to 24 Weeks of Peg-Interferon-α2b/Ribavirin or Induction-Dose Interferon-α2b/Ribavirin/Amantadine: A Non-Randomized Controlled Study , 2005, The American Journal of Gastroenterology.

[6]  Christophe Combet,et al.  Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes , 2005, Hepatology.

[7]  C. Walker,et al.  Adaptive immune responses in acute and chronic hepatitis C virus infection , 2005, Nature.

[8]  J. Hoofnagle,et al.  Mechanism of action of interferon and ribavirin in treatment of hepatitis C , 2005, Nature.

[9]  Charles M. Rice,et al.  Unravelling hepatitis C virus replication from genome to function , 2005, Nature.

[10]  J. Pawlotsky,et al.  Use of virologic assays in the diagnosis and management of hepatitis C virus infection. , 2005, Clinics in liver disease.

[11]  T. Berg,et al.  Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C , 2005 .

[12]  A. Andriulli,et al.  Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. , 2005, The New England journal of medicine.

[13]  A. Jenke,et al.  Peginterferon alfa‐2b plus ribavirin treatment in children and adolescents with chronic hepatitis C , 2005, Hepatology.

[14]  M. Manns,et al.  Early monotherapy with pegylated interferon alfa–2b for acute hepatitis C infection: Final Results of the German HEP-NET Acute HCV II Study , 2005 .

[15]  B. Rehermann,et al.  Immunology of hepatitis B virus and hepatitis C virus infection , 2005, Nature Reviews Immunology.

[16]  D. Kleiner.  The liver biopsy in chronic hepatitis C: a view from the other side of the microscope. , 2005, Seminars in liver disease.

[17]  K. Bjøro,et al.  Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study , 2004, Hepatology.

[18]  Francesco Donato,et al.  Hepatocellular carcinoma in cirrhosis: incidence and risk factors. , 2004, Gastroenterology.

[19]  L. Seeff,et al.  Aasld Practice Guideline Diagnosis, Management, and Treatment of Hepatitis C , 2003 .

[20]  P. Marcellin,et al.  Peginterferon-2a and Ribavirin Combination Therapy in Chronic Hepatitis C , 2004, Annals of Internal Medicine.

[21]  V. Paradis,et al.  Sampling variability of liver fibrosis in chronic hepatitis C , 2003, Hepatology.

[22]  E. Yu.  [Histologic grading and staging of chronic hepatitis: on the basis of standardized guideline proposed by the Korean Study Group for the Pathology of Digestive Diseases]. , 2003, Taehan Kan Hakhoe chi = The Korean journal of hepatology.

[23]  J. Hoofnagle,et al.  National institutes of health consensus development conference statement: Management of hepatitis C: 2002 — June 10–12, 2002 , 2002, Gastroenterology.

[24]  D. Thomas.  Hepatitis C and human immunodeficiency virus infection , 2002, Hepatology.

[25]  G. Davis.  Monitoring of viral levels during therapy of hepatitis C , 2002, Hepatology.

[26]  J. Hoofnagle.  Course and outcome of hepatitis C , 2002, Hepatology.

[27]  B. Bacon.  Treatment of patients with hepatitis C and normal serum aminotransferase levels , 2002, Hepatology.

[28]  M. Fried,et al.  Side effects of therapy of hepatitis C and their management , 2002, Hepatology.

[29]  M. Fried.  Side effects of therapy of hepatitis C and their management , 2002 .

[30]  William M. Lee,et al.  Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. , 2002, Gastroenterology.

[31]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[32]  F. Fabrizi,et al.  Hepatitis C infection and the patient with end‐stage renal disease , 2002, Hepatology.

[33]  Z. Hong,et al.  Mechanism of action of ribavirin in the combination treatment of chronic HCV infection , 2002, Hepatology.

[34]  T. Poynard,et al.  Interferon for interferon naive patients with chronic hepatitis C. , 2002, The Cochrane database of systematic reviews.

[35]  C. Cameron,et al.  Hepatitis C Virus RNA-dependent RNA Polymerase (NS5B) as a Mediator of the Antiviral Activity of Ribavirin* , 2001, The Journal of Biological Chemistry.

[36]  C. Trautwein,et al.  Treatment of acute hepatitis C with interferon alfa-2b. , 2001, The New England journal of medicine.

[37]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[38]  T. Heeren,et al.  Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  B. Walker,et al.  Hepatitis C virus infection. , 2001, The New England journal of medicine.

[40]  J. Arnold,et al.  The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen , 2000, Nature Medicine.

[41]  Samir K. Gupta,et al.  Pegylated interferon‐α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data , 2000 .

[42]  H. Margolis,et al.  The past incidence of hepatitis C virus infection: Implications for the future burden of chronic liver disease in the United States , 2000, Hepatology.

[43]  William M. Lee,et al.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.

[44]  P. Marcellin,et al.  Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.

[45]  Alan S. Perelson,et al.  Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy , 1998 .

[46]  L. Seeff.  Natural history of hepatitis C , 1997, Clinics in liver disease.

[47]  H. Tilg.  New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. , 1997, Gastroenterology.

[48]  P. Bedossa,et al.  An algorithm for the grading of activity in chronic hepatitis C , 1996, Hepatology.

[49]  R. Groszmann,et al.  American association for the study of liver diseases , 1992 .

[50]  J. Stockman.  Peginterferon Alfa-2b and Ribavirin for 12 vs 24 weeks in HCV Genotype 2 or 3 , 2007 .

[51]  J. McHutchison,et al.  American Gastroenterological Association technical review on the management of hepatitis C. , 2006, Gastroenterology.

[52]  M. Buti,et al.  Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. , 2006, Journal of hepatology.

[53]  T. Berg,et al.  Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. , 2005, Gastroenterology.

[54]  Robin Patel,et al.  Treatment of acute hepatitis C with interferon alfa-2b. , 2002, The New England journal of medicine.

[55]  G. Sen,et al.  Viruses and interferons. , 2001, Annual review of microbiology.

[56]  M. Alter,et al.  Epidemiology of Hepatitis C: Geographic Differences and Temporal Trends , 2000, Seminars in liver disease.

[57]  A S Perelson,et al.  Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. , 1998, Science.